argenx SE (ARGX) vs NewAmsterdam Pharma Company N.V. (NAMS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ARGX | NAMS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | LARGE | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | Netherlands | Netherlands |
| Theme | rare-disease | neuroscience |
| Price and returns | ||
| Last close | $869.33 | $19.53 |
| Return · 1 week | +5.30% | −4.59% |
| Return · 1 month | −10.59% | −17.18% |
| Return · 3 months | −0.33% | −30.20% |
| Return · year to date | +3.49% | −44.52% |
| Return · 1 year | +4.76% | −45.81% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −18.96% | −53.73% |
| 52-week high | $1,072.75 | $42.21 |
| 52-week low | $661.85 | $19.13 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $54.67B | $2.33B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $241.59M | $24.45M |
| Employees | 1,863 | 100 |
| Valuation | ||
| Price to earnings · trailing | 30.26× | n/a (negative earnings) |
| Price to earnings · forward | 26.23× | n/a (negative forward earnings) |
| Price to sales | 9.29× | 362.17× |
| Price to book | 162.29× | 4.02× |
| Enterprise value to EBITDA | 715.84× | n/a (negative EBITDA) |
| Enterprise value to revenue | 230.05× | 282.49× |
| PEG ratio | 1.02 | — |
| Earnings per share · trailing | 28.87 | -2.16 |
| Profitability | ||
| Gross margin | 89.96% | — |
| Operating margin | 36.27% | −1752.61% |
| Profit margin | 31.73% | −3644.21% |
| Return on equity | — | −36.81% |
| Return on assets | — | −20.11% |
| Growth | ||
| Revenue growth | +52.10% | −80.70% |
| Earnings growth | +50.60% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 0.56 | 0.01 |
| Current ratio | — | 9.03 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | — |
| Trend and volatility | ||
| RSI · 14 | 45.11 | 34.96 |
| ADX · 14 | 27.49 | 30.60 |
| 50-day average | $953.35 | $23.42 |
| 200-day average | $852.88 | $30.04 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.22% | 5.78% |
The full ARGX analysis
Everything this table leaves out for argenx SE: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ARGX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ARGX analysisThe full NAMS analysis
Everything this table leaves out for NewAmsterdam Pharma Company N.V.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NAMS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NAMS analysis